Skip to Content
Merck
CN

SML2303

Tosedostat

≥98% (HPLC)

Synonym(s):

2S-[2R-(S-Hydroxy-hydroxycarbamoyl-methyl)-4-methylpentanoyl-amino]-2-phenylethanoic acid cyclopentyl ester, CHR-2797

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C21H30N2O6
CAS Number:
238750-77-1
Molecular Weight:
406.47
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD13185162

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1

SMILES string

CC(C)C[C@H]([C@H](O)C(NO)=O)C(N[C@@H](C1=CC=CC=C1)C(OC2CCCC2)=O)=O

InChI key

FWFGIHPGRQZWIW-SQNIBIBYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Related Categories

Biochem/physiol Actions

Potent cell permeable, antiproliferative aminopeptidase inhibitor
Tosedostat (CHR-2797) is a potent cell permeable, antiproliferative aminopeptidase inhibitor. It has been in clinical trials for AML, pancreatic cancer and more.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000173660
0000173661
0000173661
0000173660
0000049319

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Danielle Shafer et al.
Blood reviews, 30(4), 275-283 (2016-03-15)
Acute myeloid leukemia (AML) remains a challenge to both patients and clinicians. Despite improvements in our understanding of the disease, treatment has changed minimally and outcomes remain poor for the majority of patients. Within the last decade, there have been
Raya Mawad et al.
British journal of haematology, 172(2), 238-245 (2015-11-17)
Tosedostat, an oral aminopeptidase inhibitor, has synergy with cytarabine and hypomethylating agents. We performed a Phase II trial to determine rates of complete remission (CR) and survival using tosedostat with cytarabine or decitabine in older patients with untreated acute myeloid
Caner Saygin et al.
Journal of hematology & oncology, 10(1), 93-93 (2017-04-20)
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated clinical activity, either

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service